Maynard Um
-
-
-
-
-
-
-
Guggenheim Starts Enliven Therapeutics (ELVN) at Buy
-
-
-
-
-
-
-
Enliven Therapeutics adds Scott Garland to board, Andrew Phillips resigns
-
-
-
-
-
-
-
Goldman Sachs Starts Enliven Therapeutics (ELVN) at Buy
-
-
-
-
-
-
-
Enliven Therapeutics, Inc (ELVN) Misses Q1 EPS by 7c
-
-
-
-
-
-
-
Jones Trading Starts Enliven Therapeutics (ELVN) at Buy
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Enliven Therapeutics (ELVN)
-
435,847 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

